Clinicopathological features, MCPyV status and outcomes of Merkel cell carcinoma in solid-organ transplant recipients: a retrospective, multicentre cohort study.

Autor: Ferrándiz-Pulido C; Department of Dermatology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain., Gómez-Tomás A; Department of Dermatology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain., Llombart B; Servicio de Dermatología, Instituto Valenciano de Oncología, Valencia, Spain., Mendoza D; Department of Dermatology, Fundación Jiménez Díaz, Madrid, Spain., Marcoval J; Department of Dermatology, Hospital de Bellvitge, IDIBELL, University of Barcelona, Barcelona, Spain., Piaserico S; Dermatology Unit, Department of Medicine, Università di Padova, Padova, Italy., Baykal C; Department of Dermatology, Istanbul University, Istanbul Medical Faculty, Istanbul, Turkey., Bouwes-Bavinck JN; Department of Dermatology, Leiden University Medical Center, Leiden, The Netherlands., Rácz E; Department of Dermatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands., Kanitakis J; Department of Dermatology, Edouard Herriot Hospital Group, Hospices Civils de Lyon, Lyon, France., Harwood CA; Centre for Cell Biology and Cutaneous Research, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK., Cetkovská P; Department of Dermatovenereology, Faculty of Medicine, Charles University, Pilsen, The Czech Republic., Geusau A; Department of Dermatology, Medical University of Vienna, Vienna, Austria., Del Marmol V; Service de Dermatologie, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium., Masferrer E; Department of Dermatology, Hospital Universitari Mútua de Terrassa, Barcelona, Spain., Orte Cano C; Service de Dermatologie, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium., Ricar J; Department of Dermatovenereology, Faculty of Medicine, Charles University, Pilsen, The Czech Republic., de Oliveira WR; Department of Dermatology, University of São Paulo, São Paul, Brazil., Salido-Vallejo R; Department of Dermatology, University Clinic of Navarra, School of Medicine, University of Navarra, Pamplona, Spain., Ducroux E; Department of Dermatology, Edouard Herriot Hospital Group, Hospices Civils de Lyon, Lyon, France., Gkini MA; Centre for Cell Biology and Cutaneous Research, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK., López-Guerrero JA; Laboratory of Molecular Biology, Fundación Instituto Valenciano de Oncología, Valencia, Spain.; IVO-CIPF Joint Research Unit of Cancer, Príncipe Felipe Research Center (CIPF), Valencia, Spain.; Department of Pathology, School of Medicine, Catholic University of Valencia 'San Vicente Martir', Valencia, Spain., Kutzner H; Dermatopathologie, Friedrichshafen, Germany., Kempf W; Kempf und Pfaltz Histologische Diagnostik and Department of Dermatology, University Hospital Zurich, Zürich, Switzerland., Seçkin D; Department of Dermatology, Başkent University Faculty of Medicine, Ankara, Turkey.
Jazyk: angličtina
Zdroj: Journal of the European Academy of Dermatology and Venereology : JEADV [J Eur Acad Dermatol Venereol] 2022 Nov; Vol. 36 (11), pp. 1991-2001. Date of Electronic Publication: 2022 Jun 14.
DOI: 10.1111/jdv.18256
Abstrakt: Background: The proportion of Merkel cell carcinomas (MCCs) in solid-organ transplant recipients (SOTR) harbouring Merkel cell polyomavirus (MCPyV) is unknown, as are factors affecting their outcomes.
Objective: To describe clinicopathological features of MCC in SOTR, investigate the tumoral MCPyV-status and identify factors associated with tumour outcomes.
Methods: Retrospective, international, cohort-study. MCPyV-status was investigated by immunohistochemistry and polymerase chain reaction.
Results: A total of 30 SOTR and 44 consecutive immunocompetent patients with MCC were enrolled. SOTR were younger at diagnosis (69 vs. 78 years, P < 0.001). Thirty-three percent of SOTR MCCs were MCPyV-positive vs. 91% of immunocompetent MCCs (P = 0.001). Solid-organ transplantation was associated with an increased cumulative incidence of progression (SHR: 3.35 [1.57-7.14], P = 0.002), MCC-specific mortality (SHR: 2.55 [1.07-6.06], P = 0.034) and overall mortality (HR: 3.26 [1.54-6.9], P = 0.002). MCPyV-positivity and switching to an mTOR inhibitor (mTORi) after MCC diagnosis were associated with an increased incidence of progression (SHR: 4.3 [1.5-13], P = 0.008 and SHR: 3.6 [1.1-12], P = 0.032 respectively) in SOTR.
Limitations: Retrospective design and heterogeneity of SOTR cohort.
Conclusions: MCPyV appears to play a less prominent role in the aetiopathogenesis of MCC in SOTR. SOTR have a worse prognosis than their immunocompetent counterparts and switching to an mTORi after the diagnosis of MCC does not improve progression.
(© 2022 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.)
Databáze: MEDLINE
Externí odkaz: